2 Information about crizanlizumab

Marketing authorisation indication

2.1 Crizanlizumab (Adakveo, Novartis) is indicated 'for the prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price of crizanlizumab is £1,038 for a 100‑mg vial (excluding VAT; BNF online accessed October 2021). The company has a commercial arrangement. This makes crizanlizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)